IG Farben

BASF expands e-commerce agreement with Agilis

Retrieved on: 
Monday, May 10, 2021
BASF, IG Farben, Societates Europaeae, The Holocaust, agilis, Companies, Economy of Germany, Industry economics)

b'NEWARK, N.J., May 10, 2021 /PRNewswire-PRWeb/ -- BASF has entered into a multi-year agreement with Agilis Chemicals Inc., provider of digital commerce technology for the chemical industry.

Key Points: 
  • b'NEWARK, N.J., May 10, 2021 /PRNewswire-PRWeb/ -- BASF has entered into a multi-year agreement with Agilis Chemicals Inc., provider of digital commerce technology for the chemical industry.
  • "We look forward to continuing our partnership with Agilis, making the customer online experience simple, convenient, and easy-to-use.
  • "Our mission at Agilis is to help chemical suppliers implement smart and intuitive digital commerce solutions that don\'t require them to change how they do business," says Jay Bhatia, Founder and CEO of Agilis.
  • Agilis offers chemical suppliers an easy and cost-effective way to attract and engage customers via secure digital sales and marketing channels.

BASF ranks 12 on list of DiversityInc Top 50 Companies for Diversity

Retrieved on: 
Friday, May 7, 2021
Financial markets, Depositary receipts, Equity securities, BASF, IG Farben, Societates Europaeae, The Holocaust, Companies, American depositary receipt, Economy of Germany

b'FLORHAM PARK, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- For the ninth consecutive year, BASF was named one of the Top 50 Companies for Diversity by DiversityInc, moving up two places from 14 in 2020 to 12 in 2021.

Key Points: 
  • b'FLORHAM PARK, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- For the ninth consecutive year, BASF was named one of the Top 50 Companies for Diversity by DiversityInc, moving up two places from 14 in 2020 to 12 in 2021.
  • The DiversityInc Top 50 Companies for Diversity list began in 2001, when many corporations were beginning to understand the business value of diversity-management initiatives.
  • DiversityInc is a VA certified veteran-owned business and a USBLN certified business owned by a person with a disability.
  • BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the U.S. Further information at http://www.basf.com .\n'

Insights on the Crop Protection Chemicals Global Market to 2026 - Key Drivers and Restraints - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, BASF, IG Farben, Societates Europaeae, The Holocaust, Pesticide, Food security, Companies, Physical sciences, Chemistry

b'The "Crop Protection Chemicals Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global crop protection chemical market is projected to grow at a CAGR of 5.42% to reach a market size of US$101.640 billion in 2026 from US$70.239 billion in 2019.\nThe outbreak of COVID-19 has impacted global trade which has led to socio-economic disruptions around the world.

Key Points: 
  • b'The "Crop Protection Chemicals Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global crop protection chemical market is projected to grow at a CAGR of 5.42% to reach a market size of US$101.640 billion in 2026 from US$70.239 billion in 2019.\nThe outbreak of COVID-19 has impacted global trade which has led to socio-economic disruptions around the world.
  • It is estimated that post-COVID when the economic conditions are back to normal the demand for crop protection chemicals will rise.\nThere has been a growing demand for food security across the globe and strict government regulations about it will drive the growth in the market of crop protection chemicals.
  • Heavy crop loss due to pest attacks pressurizes farmers to use crop protection chemicals further propelling its market growth.
  • This facility will supply BASF\'s patented crop protection products to farmers in the region of Asia Pacific.

More than 40,000 Cancer Claims Remain Unresolved from Proposed Bayer Monsanto Roundup Weed Killer Lawsuit Settlement

Retrieved on: 
Monday, April 26, 2021
Articles, Companies, Tort law, Aspirin, Bayer, IG Farben, Leverkusen, Industry economics), Legal liability, Product liability, Corporate law, Liability

"Bayer shareholders would like to put this significant exposure behind them, however Bayer\'s strategy will only ensure that jury trials will take place for years to come.

Key Points: 
  • "Bayer shareholders would like to put this significant exposure behind them, however Bayer\'s strategy will only ensure that jury trials will take place for years to come.
  • The largest and most diverse products liability law firm in the nation, Fears |Nachawatiwas rankedNo.
  • 1nationally in product liability filings in federal courtover the last three years.
  • For more information, visit https://www.fnlawfirm.com .\n'

Bayer Pharmaceuticals Taps Two Leaders for New Roles in the U.S.

Retrieved on: 
Tuesday, April 20, 2021
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, Drugs, Companies, Analgesics, Aspirin, Bayer, IG Farben, Leverkusen, Pharmaceutical industry in China, Heroin

\xe2\x80\x9cThe U.S. Pharmaceuticals Business is central to Bayer\xe2\x80\x99s success.

Key Points: 
  • \xe2\x80\x9cThe U.S. Pharmaceuticals Business is central to Bayer\xe2\x80\x99s success.
  • Since joining Bayer in 2016, Berrios has held multiple leadership roles in market access and operations.
  • Bayer is committed to drive sustainable development and generate a positive impact with its businesses.
  • These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com .

Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021

Retrieved on: 
Tuesday, April 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Companies, Biology, Life sciences, Aspirin, Bayer, IG Farben, Leverkusen, Biomarker, Aliqopa® (copanlisib) Injection, Vitrakvi® (larotrectinib), NUBEQA® (darolutamide), Xofigo® (radium Ra 223 dichloride) Injection, Oncology at Bayer, Bayer

Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 , taking place over two weeks on April 10-15 and May 17-21, 2021.

Key Points: 
  • Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 , taking place over two weeks on April 10-15 and May 17-21, 2021.
  • The new data reaffirm Bayer's continued efforts to investigate the clinical impact a biomarker-driven approach can have on patients.
  • Bayer will also reveal the latest data from its differentiated early pipeline across other focus areas, including precision molecular oncology and immuno-oncology.
  • Overall, these data stress Bayers commitment to continued research in some of the companys key areas of focus in oncology.

Bayer Announces Restructuring of U.S. Corporate Affairs To Support Business Priorities, Accelerated Growth Plans

Retrieved on: 
Tuesday, April 6, 2021
Health, Other Health, Other Science, General Health, Research, Science, Companies, Aspirin, Bayer, IG Farben, Leverkusen, Industry economics), Economy of Germany

Bayer today announced a reorganization of its U.S. Corporate Affairs team which will separate Communications and Public Affairs responsibilities.

Key Points: 
  • Bayer today announced a reorganization of its U.S. Corporate Affairs team which will separate Communications and Public Affairs responsibilities.
  • Roden will report in both roles to Patrick Lockwood-Taylor, President of Bayer U.S. and President, Consumer Health, North America.
  • In addition, the U.S. Corporate Engagement team, led by Al Mitchell, Vice President, U.S. Corporate Engagement, will become part of U.S. Public Affairs.
  • Lockwood-Taylor said the transformation of U.S. Corporate Affairs is aimed at supporting the key priorities and accelerated growth plans of Bayers businesses in the United States.

Dotmatics Implements ‘Data to Value’ Initiative with BASF Agricultural Solutions

Retrieved on: 
Tuesday, March 30, 2021
Science, Software, Agriculture, Research, Natural Resources, Health, Technology, Other Health, BASF, IG Farben, Societates Europaeae, The Holocaust, Companies, Economy of Germany, Industry economics)

To cope with ever more complex and comprehensive data in R&D, Dotmatics and BASF Agricultural Solutions worked together to enhance the divisions R&D IT infrastructure.

Key Points: 
  • To cope with ever more complex and comprehensive data in R&D, Dotmatics and BASF Agricultural Solutions worked together to enhance the divisions R&D IT infrastructure.
  • With a 3-step phased approach, BASF Agricultural Solutions successfully reached the goals of the Data to Value project.
  • The Dotmatics platform also allows searching across experimental and project results generated by BASF Agricultural Solutions global R&D team.
  • With Dotmatics, data scientists of BASF Agricultural Solutions now have enhanced data search, aggregation, and visual analytics capabilities.

Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine

Retrieved on: 
Monday, March 29, 2021
Health, Clinical trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Chemical compounds, Companies, Pyrimidines, Aspirin, Bayer, IG Farben, Leverkusen, Riociguat, Industry economics), Risk Evaluation and Mitigation Strategies, Rems, the REPLACE Study, Pulmonary Arterial Hypertension, Adempas® (riociguat), Bayer

For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.

Key Points: 
  • For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.
  • Adempas, the first sGC stimulator of this collaboration, is developed by Bayer and MSD.
  • For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.
  • Our online press service is just a click away: www.bayer.us/en/newsroom
    BAYER, the Bayer Cross, and Adempas(R) are registered trademarks of Bayer.

Enterprise Imaging Solutions Market Revenue to Cross USD 2.2 Bn by 2027: Global Market Insights Inc.

Retrieved on: 
Tuesday, March 9, 2021
Medical imaging, Companies, Agfa, Agfa-Gevaert, IG Farben, Brands, Industry economics), Philips, GE Healthcare, Gevaert, Cloud computing

Thus, enterprise imaging solutions offer all the healthcare providers a platform where they can securely access, view and share imaging data to provide better patient care services.

Key Points: 
  • Thus, enterprise imaging solutions offer all the healthcare providers a platform where they can securely access, view and share imaging data to provide better patient care services.
  • The increasing deployment of VNA, image exchange and universal viewer solutions in the enterprise imaging platform are further driving the demand or universalization of image management in the enterprise imaging solutions market.
  • The enterprise imaging solutions market for the cloud-based deployment segment accounted for USD 704 million in 2020.
  • Some of the major companies operating in the enterprise imaging solutions market are IBM Corporation, GE Healthcare, Koninklijke Philips N.V., and Agfa-Gevaert, among others.